Authors
Latest:
Future Perspectives and Unmet Needs in CLLThe panelists conclude their discussion by offering future perspectives on CLL treatment, emphasizing remaining areas of unmet needs in the treatment landscape.
Latest:
Improving the RCC Patient Journey and Future Therapeutic DirectionsPanelists discuss areas for improvement in the RCC journey from the patient perspective, including the impact of emerging research on their experience, and explore therapeutic approaches and clinical research areas that show promise for improving outcomes in advanced RCC, with a focus on novel targets and mechanisms of action in development.
Latest:
Key Takeaways on Evolving Treatment Landscape in Multiple MyelomaThe expert panel provides closing remarks on exciting developments in the evolving treatment landscape in multiple myeloma.
Latest:
Brandon Sheffield, MD, Details NGS Benefits Vs Single-Gene Testing in NSCLCAt the 2022 WCLC, Brandon Sheffield, MD, presented data demonstrating the advantage of next-generation sequencing over other biomarker testing strategies in patients with non–small cell lung cancer.
Latest:
PSMA PET Imaging Agents: Image Quality and Diagnostic PerformancePanelists discuss how PSMA PET imaging utilizes various tracers, each with distinct properties influencing image quality and diagnostic accuracy. Fluciclovine F18 (Axumin) is primarily used for detecting recurrent prostate cancer, offering moderate sensitivity but lower specificity compared with PSMA-targeted agents. Gallium Ga-68 gozetotide (Illuccix) provides high sensitivity and specificity for prostate cancer lesions; however, its shorter half-life and limited availability may restrict widespread use. Piflufolastat F18 (Pylarify) combines the benefits of F18’s longer half-life with high image resolution, enhancing detection accuracy. Similarly, flotufolastat F18 (Posluma) leverages F18’s favorable imaging characteristics, offering high-quality images and reliable lesion detection.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical TrialsThese data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
Latest:
CAR T-Cell Therapy in Multiple Myeloma: Lessons Learned and Key TakeawaysPanelists discuss how UCSF Health has learned that successful integration of CAR T-cell therapy in multiple myeloma requires multidisciplinary collaboration, patient selection optimization, and management of toxicities. Future research includes exploring CAR T-cell therapy in earlier treatment lines and combining it with novel agents to enhance efficacy.
Latest:
Management of Testicular Germ Cell Tumor With Somatic-Type MalignancyIn this installment of Clinical Quandaries, Bendu Konneh, BS, and colleagues present a case of a 21-year-old male with a 4-month history of progressive swelling in the right testicle.
Latest:
Value of Collaboration in Managing Patients With Metastatic RCCClosing out their discussion on the management of metastatic renal cell carcinoma, panelists highlight the value of collaborative care in improving patient outcomes.
Latest:
Camizestrant/Ribociclib Improves PFS and Responses in ER+/HER2– Breast CancerPatients with ER+/HER2– advanced breast cancer saw positive efficacy and safety data following treatment from the SERENA-1 trial.
Latest:
Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal AdenocarcinomaDaniel V. T. Catenacci, MD, and colleagues present findings from a study of circulating tumor DNA as a predictive biomarker for gastric and gastroesophageal cancer.
Latest:
Genomic Predictors Associated With Exceptional Response to Systemic Therapy in Advanced Pancreatic CancerSuneel K. Kamath, MD, et al investigated exceptional responders and the correlation of nonsynonymous mutations for patients with advanced pancreatic cancer.
Latest:
Peter Humphrey, MD, PhD, Discusses Current Role of Pathology in RCCAt the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about the role of pathology in renal cell carcinoma.
Latest:
CAR T in R/R MM: Key Takeaways and PearlsPanelists discuss how successful implementation of chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (R/R MM) depends on early referral, coordinated care between academic and community centers, standardized protocols for patient management, and careful consideration of product selection and timing based on individual patient factors.
Latest:
Taste Change Data May Inform Radiotherapy Strategy in Head and Neck CancerFindings may help providers and patients with head and neck cancer consider whether to proceed with radiotherapy modalities, such as proton therapy or IMRT.
Latest:
HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in CareClosing out their review of the HER2+ metastatic breast cancer treatment landscape, expert oncologists look forward to future evolutions in the paradigm.
Latest:
Closing Thoughts on Bispecific Antibodies and the Future of R/R MM TreatmentThe panel looks to the future of relapsed/refractory multiple myeloma treatment and the remaining unmet needs for patients.
Latest:
Factors in Selecting Therapy for HER2+ Metastatic Breast Cancer With CNS DiseaseShared consideration on the factors that dictate selection of optimal therapy for patients with HER2+ breast cancer and brain metastases.
